Company ProfilePremium

CLASSYS Inc.

Company Profile Analysis

Ticker: 214150.KQ주식회사 클래시스

ESOMAR 23 Corporate BadgeISO Certifications Badge
CLASSYS Inc. - Company showcase

Year Founded & Workforce

2007

537 Employees

CLASSYS Inc. logo

CLASSYS Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CLASSYS Inc. Overview

CLASSYS is South Korea's largest listed energy-based aesthetic device (EBD) company by market capitalisation and profitability. It runs a "razor-and-blade" model: it installs high-intensity focused ultrasound (HIFU), monopolar radiofrequency (RF), microneedle RF (MNRF) and laser platforms in clinics, then sells high-margin, procedure-linked cartridges and tips. Its flagship HIFU franchise, Shurink, sold abroad as Ultraformer, and its monopolar RF system Volnewmer, sold in the US as Everesse, have built an installed base of more than 48,000 cumulative units since founding (IR Book 2Q26). The company has posted operating margins near 50% for five consecutive years. Bain Capital has controlled it since 2022. Since then it has merged with Ilooda (October 2024) to add MNRF and lasers, bought its Brazilian distributor MedSystems (2025–26), and begun moving to direct sales in Japan and Latin America. It now faces a margin reset from direct-distribution costs, a slowing Korean market, a cut to 2026 guidance, a stock down more than 60% from its high, and an unresolved private-equity exit.


What the company does

CLASSYS designs, manufactures and sells non-invasive and minimally invasive aesthetic medical devices, together with their consumables, to dermatology and plastic-surgery clinics and aesthetic practices. It also sells home-use beauty devices and cosmetics. After merging with Ilooda in October 2024, management describes the portfolio as covering the four main EBD technology classes: HIFU, monopolar RF, MNRF and lasers (Source: Classys merger completion release, Metro Seoul / Medigate News, 2–4 Oct 2024). The company's 2Q26 disclosure says it sells in more than 80 countries, though press releases in 2025 cited 60–70. The difference reflects partner coverage versus active markets (Source: Quartr summary of 1H26 half-year report; Wanted company profile; Wikipedia).

Business and revenue model

Revenue stream (FY2025, KRW Bn)Amount% of revenueNature
Devices174.051.7Capital equipment, one-off
Consumables154.645.9Recurring, procedure-linked
Homecare (B2C devices)7.32.2Consumer product
Rentals (Korea)0.90.3Device leasing
Total336.8100.0—

The model is an installed-base platform. A device sale carries a one-off margin and establishes the clinic relationship. Each procedure then consumes a proprietary cartridge (HIFU) or tip (RF/MNRF), which produces recurring revenue. Management has said gross margin approaches 80% when the consumables mix exceeds 50% (Source: Hankyung, 8 May 2024, 1Q24 results commentary).

Source: IR Book 4Q25, "Sales by Brand" table, FY2025. Percentages are derived.

There is no meaningful subscription or licensing revenue. From 2Q26 the company also books commission revenue in Japan as it moves to direct sales there (Source: IR Book 2Q26, gross-profit commentary).

Value-chain position

Historically CLASSYS was a designer-manufacturer that exported through exclusive national distributors, such as MedSystems in Brazil, Cartessa Aesthetics in the US and partners in Thailand. It is now integrating forward into distribution:

Brazil, Colombia, Argentina: acquired the MedSystems group (77.5% of JL Health plus 100% of the Colombian and Argentine distributors). The deal was agreed in October 2025 and consolidated from March 2026.

Japan: Classys Japan was established in 2024. Management targets a 100% transition to direct sales (IR Book 2Q26, 2H26 initiatives).

Korea: sells direct to clinics.

US and Europe: distributor-led. Cartessa handles the US.

Customers and end-markets

Customers are dermatology clinics, plastic-surgery clinics, aesthetic chains and medspas. In Brazil they include more than 15,000 hospitals and aesthetic spas served by MedSystems (MedSystems IR Book, Oct 2025). Retail and e-commerce consumers buy the homecare line. The end market is non-surgical lifting, tightening, skin rejuvenation and vascular/pigment treatment. Demand comes from consumer spending on "well-aging" procedures, medical tourism (inbound tourism to Korea is cited as a consumables driver by LS Securities, June 2025) and the global shift toward minimally invasive procedures.

Company's self-description and independent characterisation

The company describes itself as a global medical aesthetics platform with end-to-end EBD solutions. It claims to be the only company able to offer personalised, combined-procedure experiences across all major energy modalities (paraphrasing CEO Yoon Jun-oh, Asia Economy, 12 Oct 2026). It sets a target of US$1 billion in revenue by 2030 (IR materials; Edaily, Oct 2026).

Independent characterisation: CLASSYS is a highly cash-generative, mid-sized device company. Its economics resemble a consumables franchise: gross margin 77–79% and EBITDA margin 53–55% in FY2024–25. That profile is now being diluted on purpose by vertical integration into lower-margin distribution (MedSystems EBITDA margin in the low teens; BizWatch, Jan 2026) and by heavier spending on marketing, R&D and senior hires. The strategic question is whether direct control of channels in Latin America and Japan, plus entry into the US and China, can sustain the 30–40% growth that historically justified premium multiples. The stock's de-rating in 2026 shows the market doubts it.

Strategy

Stated long-term targets

At the Ilooda merger (Oct 2024) the company set 2030 targets (Medigate News, 4 Oct 2024):

  • Revenue of at least US$1 bn and an operating margin of at least 50% by 2030.

  • Five blockbuster-class platforms.

  • Overseas procedure volume per platform growing at least 5% a year.

  • No. 1 installed base in lifting and tightening devices in the US and China.

  • Direct operations in five strategic countries.

  • A 20% cut in device and consumable unit costs.

Brazilian coverage of the July 2026 CEO appointment described the target as about US$730 m with a 50% margin by 2030 (Times Brasil, 15 Jul 2026). This is probably a currency conversion of a KRW 1 trillion target. Korean sources and the Oct 2026 CCO announcement still cite US$1 bn. The difference is unresolved.

2026 strategic pillars (IR Book 4Q25 guidance slide; paraphrased)

  1. Direct operations in Brazil, Latin America and Japan to improve profit structure: recognise revenue at end-user prices, capture the distributor margin, and strengthen training and service for customer lock-in.

  2. Scaled growth in the US and Europe: wider European adoption and RF leadership in the US with Quadessy and Everesse. US approval of Ultraformer is expected in 2027.

  3. Volnewmer/Everesse as the "next global flagship": annual unit sales above 2,000, succeeding Ultraformer, which sells more than 3,000 units a year.

  4. Quadessy and lasers: more than 1,000 Quadessy units a year; establish it as the main MNRF expansion driver.

  5. Korea: lead combination-procedure trends across Volnewmer, Shurink Universe and Fortra.

  6. Home beauty: expand retail distribution for Shrink Home Lift-to-Glow.

  7. China market entry: distributor agreement signed; rollout follows Volnewmer approval.

2H26 initiatives (IR Book 2Q26)

Global: keep growth momentum and accelerate China entry.

Korea: drive new-product sales, strengthen combination-treatment marketing and package promotions.

Japan: stabilise direct sales, complete the 100% move to direct, and expand network-clinic coverage.

South America: prioritise a top-line turnaround through B2B2C marketing.

New-management agenda (Jul–Oct 2026)

CEO Yoon's four stated priorities (SmartToday; Medical Times, 15 Jul 2026):

  1. Faster global expansion using global expertise.

  2. Next-generation products, services and platforms that combine AI, software and data. The goal is "first-of-kind" products built on the company's energy-device technology and accumulated procedure data.

  3. A stronger business portfolio and new growth engines.

  4. Better company-wide management systems and execution.

Supporting moves: the GTM Center (Jul 2026), the CTO hire (Aug 2026) and the CCO hire (Oct 2026). The CCO's remit covers entry and growth in the Americas, China and Europe, leadership in Korea, and data- and AI-driven go-to-market operations.

ESG and cost programmes

  • Cost: 20% unit-cost reduction target (2024), plus cost-saving and unit-cost initiatives cited in 3Q25 commentary.

  • ESG commitments: none identified.

Medium-term financial guidance

Guidance itemOriginalRevisedSource
FY2025 revenueKRW 340–360 bn (raised after 1Q25)Actual KRW 336.8 bn, just below the low endIR Book 1Q25; IR Book 4Q25
FY2026 revenueKRW 470–510 bn (midpoint 490)KRW 445 bn (12 Aug 2026)IR Book 4Q25; Edaily, Aug 2026
2030 revenueat least US$1 bnunchangedAsia Economy, Oct 2026
2030 operating marginat least 50%unchangedMedigate News, Oct 2024

The revised KRW 445 bn guidance implies 2H26 revenue of about KRW 252.3 bn, up about 43% on 2H25 (KRW 176.4 bn). That requires a sharp step-up from the 1H26 run rate (derived).

Products & Services

Prices for devices and consumables are not publicly disclosed. Launch years are given only where a source confirms them.

HIFU platforms (lifting and tightening)

ProductDescription and capabilitiesTarget customerLaunch / latestNotes
Shurink (Korea) / Ultraformer III (export)First-generation flagship HIFU. Delivers focused ultrasound at set dermal and subdermal depths to create thermal coagulation points that stimulate collagen. Uses cartridges.Dermatology and aesthetic clinicsKorean installed base 3,700+ (end-2025).Shurink series cumulative global sales exceeded 19,000 units by Aug 2025 (Venture Square, Aug 2025)
Shurink Universe (Korea) / Ultraformer MPT (export)Second-generation HIFU adding an "MPT" micro-pulsed mode alongside conventional mode, for faster, more comfortable treatment. Core growth driver of 2023–25.Clinics; aesthetic chainsKorean launch around 2022. CE certification Aug 2025.Korea installed base 2,700+; ex-Korea Ultraformer installed base 14,000+ (IR Book 4Q25). Record overseas quarterly sales in 2Q26.
Ultraformer MPT PLUSNext-generation HIFU being tested in a US pivotal study for submental and neck liftingUS physicians (FDA pathway)In clinical trialFDA IDE G250041. Multicentre, randomized, triple-masked non-inferiority trial against Merz's Ulthera System (ClinicalTrials.gov NCT07229430, recruiting). Company targets US approval in 2027; Daishin expects 2028.

Monopolar RF

ProductDescription and capabilitiesTarget customerLaunch / latestNotes
Volnewmer (Korea, Asia, LatAm, EU) / EVERESSE (US)Non-invasive monopolar RF tightening system with water-cooled tips. Positioned against Thermage.Dermatology and plastic-surgery clinics; premium chainsKorea 2023. US FDA clearance about early 2024; US launch Oct–Nov 2024 via Cartessa. Taiwan TFDA Jul 2024. EU CE MDR May 2025.Cumulative sales over 2,000 by Aug 2025. Installed base 2,200+ ex-Korea and 1,000+ Korea at end-2025. Management calls it the "next global flagship" with annual unit sales above 2,000. A completed non-inferiority trial compared it with Thermage CPT (NCT06657365); an elasticity pilot is also registered (NCT06816069). China launch expected after NMPA approval (Samsung Securities expects approval Dec 2026; Daishin expects launch 2027).

Microneedle RF (MNRF)

ProductDescription and capabilitiesTarget customerLaunch / latestNotes
Quadessy (spelled "Qudessy"/"Quadsae" in some press)Hybrid MNRF combining invasive microneedle and non-invasive RF deliveryClinics treating texture, scars, laxityLaunched Jul 2025. An improved version reflecting customer feedback was relaunched in Korea in 2Q26.Management target above 1,000 units a year as global rollout proceeds. Korean sales were weak in 1H26, with domestic sales paused and then resumed in 2Q26 (Kiwoom, Jul 2026; IR Book 2Q26). US sales progressing per Kiwoom (Aug 2026).
Secret series (Ilooda legacy, e.g. Secret RF)Fractional MNRF platformDermatology clinics, mainly US and Europe pre-mergerPre-mergerMore than 5,000 cumulative units before the merger (Medigate News, Jun 2024)

Lasers

ProductDescription and capabilitiesTarget customerLaunch / latestNotes
Reepot (Ilooda legacy)Vascular / pigment laserDermatology clinicsPre-mergerContributed to Korean device sales in 2025. Created a high base in Korea, which explains part of the 2Q26 device decline (IR Book 2Q26).
FortraNew laser product described by management as a "first kind of laser"Clinics; combination-procedure protocols2025–26Used in Korean combination protocols with Volnewmer and Shurink Universe (IR Book 4Q25 guidance slide). Laser sales grew strongly in Europe in 2Q26.

Consumables

HIFU cartridges: for Shurink, Shurink Universe and Ultraformer, in multiple depths and modes.

RF tips: for Volnewmer/Everesse.

MNRF tips: for Quadessy and the Secret series.

Consumables were 45.9% of FY2025 revenue. In 2Q26, overseas consumables kept growing at more than 30% YoY as the installed base expanded. Korean consumables fell 15.1% YoY because of a high Shurink Universe base and a wider range of competing treatments (IR Book 2Q26).

Homecare and cosmetics (B2C)

Product / brandDescriptionNotes
Shrink Home "Lift-to-Glow"At-home beauty device under the Shurink brandLaunched 28 Nov 2025 (IR Book 4Q25). Homecare revenue was KRW 7.3 bn in FY2025 and KRW 3.9 bn in 1H26.
SkedermHome-care device and skincare brand. Earlier products included Touchwave and others.Asia Economy, Oct 2020
ShurinkRX / Skederm cosmeticsPost-procedure skincareKRW 0.9 bn, 1% of 1Q25 revenue (IR Book 1Q25)
CluedermAesthetic-shop device brandAbout 5.7% of revenue in 2020 (Daishin, 2021). Current contribution not separately disclosed.

Services

Clinical education: Classys Academy and MedSystems Academy in Brazil. The Classys Global Customer Summit in Japan (Nov 2025) had about 150 Asian physicians.

Customer financing and education services: through JL Health's non-distribution subsidiaries in Brazil (MedSystems IR Book).

Device rentals: in Korea (KRW 0.9 bn in FY2025).

Financial Narrative

Income statement

Sources: Revenue, OP and net income for FY2021–25 from the DART-derived summary on Butler.works and IR Book 4Q25. Gross profit, EBITDA and pre-tax for FY2024–25 from IR Book 4Q25. FY2023 EBITDA is derived from the 52% EBITDA margin cited in the Quartr summary of 2Q24 materials.

Sources: EPS from the Kiwoom Securities report, 16 Jul 2026. FY2025 DPS from the Quartr 1H26 summary and Samsung Securities (payout 49.4%, total KRW 65.2 bn).

Derived. Revenue CAGR FY2021–25 is 35.3%, which matches the company's own 35% (IR Book 4Q25).

Commentary. Over FY2021–25 revenue grew 3.3x while operating margin stayed between 48.6% and 51.4%. Few listed medical-device companies have done this. Margin resilience came from (1) the rising consumables share, (2) cost-down programmes on core devices, which management targets at a 20% unit-cost reduction (merger release, Oct 2024), and (3) operating leverage on a lean HQ of about 530 people. Gross margin fell 1.2 points in FY2025 because devices took a larger share of the mix and lower-margin Ilooda products rose to 15% of revenue. Tighter SG&A (26.9% of revenue, down from 28.3%) and a bad-debt reversal on Brazilian receivables in 4Q25 offset this. Below the operating line, FY2025 net income benefited from a sharply lower effective tax rate: tax expense was KRW 13.3 bn on pre-tax KRW 168.7 bn, about 7.9%, against about 23.5% in FY2024. Management did not explain the cause in the materials reviewed. That benefit will not recur in FY2026: 1H26 tax was KRW 22.8 bn on KRW 81.5 bn pre-tax, about 28%.

Quarterly trajectory (the 2026 inflection)

Sources: IR Books 1Q25, 3Q25, 4Q25 and 2Q26. 1Q25 EBITDA and net income are derived from 1H25 totals minus 2Q25. Yonhap reported 2Q26 net income of KRW 25.5 bn (−3.6% YoY) from the preliminary filing, while the IR Book shows KRW 28.4 bn attributable. The difference is most likely the definition (total vs attributable, or preliminary vs final) and should be reconciled against the half-year report.

Commentary. 1Q26 broke a long run of profit growth: OP fell 4.1% YoY and missed consensus by 15–17% (Kyobo; Eugene). Causes were acquisition fees for MedSystems and China entry, higher marketing, and unrealized-profit elimination on stock shipped to new subsidiaries. In 2Q26 revenue crossed KRW 100 bn for the first time, but OP grew only 2.2% and the operating margin fell 10 points YoY to 41.6%. Korea revenue dropped 25.3% YoY. Revenue has grown YoY for 21 consecutive quarters (Eugene, Aug 2026), but earnings growth has stalled.

Balance sheet

Source: IR Book 4Q25 (FY2022–FY2025) and IR Book 2Q26 (FY2023–Jun-2026). Working capital is derived.

Debt. The only borrowing the company names is an HQ building loan of KRW 61 bn. It sat in non-current liabilities at end-2025 and was reclassified to current by June 2026, meaning it falls due within 12 months. At June 2026 there were also South American borrowings of undisclosed amount (IR Book 2Q26). The company has no bonds outstanding (Kyobo estimates, 2026). Before 2024, the company refinanced short-term debt into long-term (IR Book 4Q25).

Net cash at FY2025 was about KRW 147 bn if the HQ loan is the only borrowing (derived). At June 2026, cash of KRW 136.1 bn less the KRW 61 bn HQ loan gives about KRW 75 bn before South American borrowings.

Goodwill and intangibles rose from KRW 2.8 bn (FY2023) to KRW 140.9 bn (FY2024) with the Ilooda merger, and to KRW 162.6 bn (Jun 2026) with MedSystems goodwill and capitalized clinical costs.

Commentary. Receivables doubled in six months to KRW 98.4 bn because South American receivables were consolidated. MedSystems sells to clinics on instalment terms and provides customer financing services, so consolidated working capital now carries Brazilian consumer and clinic credit risk. Inventories more than doubled to KRW 64.9 bn for the same reason. Cash fell by KRW 71.5 bn in 1H26 after the KRW 65.2 bn FY2025 dividend and the MedSystems purchase. The balance sheet remains strong, with equity at about 72% of assets, but it is no longer the cash-rich, asset-light structure it was before 2024.

Cash flow

Qualitatively, management attributes the rise in cash from KRW 158.0 bn to KRW 207.6 bn during FY2025 to strong operating performance (IR Book 4Q25), despite capex on HQ and plant buildings and the integration of the former Ilooda industrial facility. One reference point: EBITDA of KRW 185.2 bn less an estimated tax of about KRW 13 bn suggests strong underlying cash generation in FY2025. That figure is not a reported free cash flow.

Ratios

All derived from IR Books 4Q25 and 2Q26. ROE and ROA use average balances and parent-attributable net income where available. Financial expenses include FX losses, so the coverage ratio is conservative. Net debt/EBITDA is negative (net cash) in every year shown.

Commentary. ROE of 26–29% on a largely unlevered balance sheet reflects high margins rather than leverage. The FY2024 dip in the current ratio came from short-term borrowings that were later refinanced into long-term debt. The June 2026 reclassification of the HQ loan will compress the ratio again, though liquidity is not under pressure. Inventory days fell sharply in FY2025, which the company attributes to better production management.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Category (KRW Bn)FY2024FY2025

Device revenue

123.9174.0

Device revenue - Global

94.9128.0

Device revenue - Korea

29.045.9

Consumables revenue

113.3154.6

Consumables revenue - Global

67.095.5

Consumables revenue - Korea

46.359.2

Homecare revenue

4.77.3

Rentals revenue (Korea)

1.00.9

Total revenue

242.9336.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Category growth and mix (%)

Category growth and mix (%)FY2024FY2025

Device YoY growth (%)

—40.4

Consumables YoY growth (%)

—36.5

Homecare YoY growth (%)

—54.5

Device share of revenue (%)

51.051.7

Consumables share of revenue (%)

46.645.9

Homecare share of revenue (%)

1.92.2

Segment Revenue

Category (KRW Bn)1H251H26

Legacy business total

160.4175.8

Legacy - Global

105.9130.0

Legacy - Korea

54.545.8

Device

80.691.4

Device - Global

58.877.2

Device - Korea

21.814.2

Consumables

76.280.2

Consumables - Global

46.252.5

Consumables - Korea

30.027.7

Homecare

3.23.9

Rentals

0.40.3

South America adds

0.016.9

Consolidated revenue

160.4192.7

2Q26 profitability (%)

2Q26 profitability (%)Standalone (HQ)Consolidated

Gross margin

76.972.5

Operating margin

50.841.6

Net margin

42.926.9

EBITDA margin

55.045.6

Income Statement

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Revenue

100.6141.8180.1242.9336.8

Gross profit

———191.1261.1

Operating income

51.768.989.6122.4170.6

EBITDA

——93.7129.7185.2

Pre-tax income

———127.9168.7

Net income (consolidated)

43.875.474.297.5132.0

Net income attributable to parent

———97.9131.9

Per-share metric (KRW)

Per-share metric (KRW)FY2024FY2025

Basic EPS

1,5172,014

Dividend per share

—1,000

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

———78.777.5

Operating margin

51.448.649.850.450.7

EBITDA margin

——52.053.455.0

Net margin

43.553.241.240.139.2

Revenue growth YoY

—41.027.034.938.6

Financial Analysis

Metric (KRW Bn)1Q252Q253Q254Q251Q262Q26

Revenue

77.183.383.093.487.2105.5

Gross profit

61.364.063.772.065.076.5

Operating income

38.843.037.651.237.243.9

EBITDA

42.346.741.354.941.048.1

Net income attributable

29.826.533.142.633.628.4

Operating margin (%)

50.351.645.354.842.741.6

Balance Sheet

Metric (KRW Bn)FY2022FY2023FY2024FY2025Jun-2026

Total assets

331.4375.4608.4704.6774.7

Current assets

147.8185.7234.2295.8317.7

Cash and equivalents (incl. ST instruments and FVPL)

111.6136.9158.0207.6136.1

Inventories

23.419.430.030.164.9

Accounts receivable

6.917.336.948.498.4

PP&E

104.2139.0193.2199.7206.0

Investment property

74.741.129.429.329.2

Intangible assets incl. goodwill

1.52.8140.9139.6162.6

Current liabilities

36.229.2128.980.2198.9

Non-current liabilities

65.662.726.872.920.7

Total liabilities

101.991.9155.7153.1219.6

Total equity

229.6283.5452.6551.5555.1

Working capital (CA − CL)

111.6156.5105.3215.6118.8

Dividends & Capital Returns

Metric (KRW Bn)FY2025

Dividend declared for the FY

65.2

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

—28.926.626.3

ROA (%)

—21.019.920.1

Current ratio (x)

4.086.361.823.69

Liabilities to equity (x)

0.440.320.340.28

Asset turnover (x)

—0.510.490.51

Receivable days (DSO)

—355552

Inventory days (on COGS)

——211145

OP / total financial expenses (x)

——19.715.8

Revenue by geography (KRW Bn)

Revenue by geography (KRW Bn)FY2024FY2025

Global (overseas) revenue

163.6224.7

Korea revenue

79.4112.2

Overseas share of revenue (%)

67.466.7

Region revenue (KRW Bn)

Region revenue (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Korea

30.253.963.079.4112.2

APAC ex-Korea

35.236.946.875.397.7

Americas

15.129.848.655.957.3

EMEA

19.119.921.634.070.7

Total

100.6141.8180.1242.9336.8

Region growth YoY (%)

Region growth YoY (%)FY2022FY2023FY2024FY2025

Korea

78.516.926.041.3

APAC ex-Korea

4.826.860.929.7

Americas

97.463.115.02.5

EMEA

4.28.557.4107.9

Country revenue (KRW Bn)

Country revenue (KRW Bn)FY2024

Brazil

47.1

Thailand

22.0

Japan

14.2

Capital Markets

MeasureValueBasis / source

Last close

KRW 28,350

19 Oct 2026 (AlphaSquare)

52-week high / low

KRW 77,600 / 26,550

AlphaSquare

Drawdown from 52-week high

-63.5%

Derived

Year to date

about -51%

Against KRW 58,100 on 9 Jan 2026 (Kiwoom); derived

1-year

about -44%

Against KRW 50,600 on 28 Oct 2025 (Kiwoom); derived

3-year

about -25% (indicative)

Kiwoom's Nov 2023 initiation implies about KRW 37,000–38,000 at the time; approximate

Valuation Multiples

MultipleCLASSYSBasis

Market cap (KRW Bn)

1,849

65,235,659 shares × KRW 28,350

Enterprise value (KRW Bn)

1,774

Market cap less about KRW 75 bn net cash (Jun 2026 cash 136.1 less HQ loan 61; South American borrowings excluded because undisclosed)

P/E trailing, FY2025 EPS (x)

14.1

EPS KRW 2,014

P/E LTM (x)

13.4

LTM net income about KRW 137.7 bn (2H25 + 1H26)

P/E 2026E (x)

12.8

Daishin 2026E EPS KRW 2,222 (Aug 2026)

EV/EBITDA LTM (x)

9.6

LTM EBITDA KRW 185.3 bn

EV/Sales LTM (x)

4.8

LTM revenue KRW 369.1 bn

P/B (x)

3.4

Jun 2026 equity about KRW 549.5 bn attributable (consistent with the 3.36x on Judal, Oct 2026)

Dividend yield (%)

3.5

FY2025 DPS KRW 1,000 on KRW 28,350

Analyst Ratings & Targets

BrokerDateRatingTarget (KRW)

Daishin

Aug 2026

Buy

60,000 (−26%)

Kiwoom

13 Aug 2026

Buy

54,000

Mirae Asset

Aug 2026

Buy

64,000

Eugene

Aug 2026

Buy

67,000

Samsung

22 Jul 2026

Buy

70,000

Kyobo

23 Jul 2026

Buy

70,000

IBK

23 Jul 2026

Buy (initiation)

62,000

Dividend metric

Dividend metricFY2025

DPS (KRW)

1,000

Total dividend (KRW Bn)

65.2

Payout ratio (%)

49.4

Analyst Conclusions

Management guidance

  • FY2026 revenue: KRW 445 bn (revised 12 Aug 2026, from KRW 470–510 bn). This implies 2H26 revenue of about KRW 252 bn, +43% YoY.

  • No explicit FY2026 operating-margin guidance. Standalone OPM is said to remain above 50%.

  • 2030: revenue of at least US$1 bn and OPM of at least 50%.

Consensus expectations

Estimate (KRW Bn)FY2025AFY2026EFY2027E
Revenue, Kiwoom (Jul 2026)336.8448.2595.7
Operating income, Kiwoom (Jul 2026)170.6208.2283.2
Operating income, Eugene (May 2026)170.6217.3277.9
Operating income, Kyobo (May 2026)170.6220.8290.2

These were mostly published before the 2Q26 guidance cut. Post-cut estimates are likely lower. Eugene's post-2Q26 forecast for 3Q26 is revenue KRW 121.2 bn and OP KRW 59.7 bn.

Bull case

  1. The core business is intact. Standalone OPM of 50.8% and GPM of 76.9% in 2Q26 show the HQ franchise has not eroded. The consolidated margin decline is mostly structural dilution from distribution, not price erosion.

  2. Overseas growth is broad-based. Legacy global revenue grew 27.6% YoY in 2Q26, with records in Europe, North America and Thailand and Ultraformer's best-ever overseas quarter. This momentum is independent of Korea.

  3. The valuation reflects a lot of bad news. About 13x LTM earnings, about 9.6x EV/EBITDA and a 3.5% yield for a company with about 26% ROE. Catalysts include China Volnewmer approval, the US HIFU pivotal readout and a possible change-of-control premium.

Bear case

  1. Growth quality is deteriorating. Korea fell 25% in 2Q26, Quadessy needed a relaunch, guidance was cut, and the 2H26 guidance implies a +43% YoY step-up that may itself be at risk.

  2. Vertical integration lowers the margin ceiling. MedSystems' EBITDA margin is in the low teens, and Latin American receivables have doubled consolidated AR. The "50% OPM" identity may not return at group level.

  3. Overhang and governance. Bain still holds about 46–49%, has sold twice at discounts, carries KRW 930 bn of share-secured holdco debt, and has failed to sell control at its asking price. CEO turnover adds uncertainty.

Catalysts and monitorables (next 12 months)

  • 3Q26 results (expected around mid-November 2026): Korean recovery, South American top line, consolidated OPM.

  • Delivery against the KRW 445 bn FY2026 guidance (FY results around Feb 2027) and the FY2027 guidance.

  • Volnewmer NMPA (China) approval, expected around Dec 2026, and first shipments.

  • Progress and readout of the Ultraformer MPT PLUS IDE study; timing of the FDA submission.

  • Any Bain transaction: control sale, further block sales, or holdco refinancing stress.

  • The new team's strategy (CEO, CTO, CCO): possible AI/data product roadmap and an investor day.

  • Receivable days and bad-debt trends in South America.

  • FY2026 dividend and buyback decisions, which support the yield-based floor.

Analyst verdict

CLASSYS is two companies on one ticker. The first is a highly profitable Korean device-and-consumables franchise. It still earns about 51% operating margins at the parent level, keeps growing overseas consumables above 30% a year, and has a deep HIFU installed base that few rivals can match on unit economics. The second is a company in transition. It is spending to become a vertically integrated global aesthetics platform through Brazilian distribution, direct sales in Japan, US and China entry, and an AI agenda. A newly assembled leadership team, including a Samsung strategist CEO, a former Bain & Company partner as CCO and a SAIT-trained CTO, runs it under a private-equity owner that has spent two years trying to exit.

The market has shifted from valuing the first company to doubting the second. A 64% drawdown, a guidance cut, two quarters of earnings misses and three CEOs in eight months together justify a lower multiple. At about 13x trailing earnings and under 10x EV/EBITDA, however, the shares now price CLASSYS below a mature Korean peer such as Wontech on some measures, despite superior margins and scale.

The investment case therefore rests less on 2026 numbers and more on evidence over the next two to four quarters. Investors need to see Korean revenue stabilise and South American revenue grow at margins that rebuild consolidated operating margin toward the mid-40s. They also need confirmation of the China and US regulatory milestones. If 3Q–4Q26 show a credible path to the revised guidance and China approval arrives on time, the valuation gap and a possible Bain-driven change-of-control process give asymmetric upside. If the 2H26 ramp falls short, further estimate cuts and continued overhang could keep the stock range-bound despite strong free-cash characteristics. Stance: cautiously constructive on a 12–18-month view, with high execution risk. The near term depends on the 3Q26 print and the FY2027 guidance.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAgeSource

Yoon Jun-oh

Representative Executive Officer and CEO

Since 15 Jul 2026

Former EVP, Samsung Electronics. Software engineer, marketing and planning roles at Samsung Korea and US. Samsung Group Future Strategy Office strategy team 2009–18, covering portfolio strategy and large M&A. Helped lead the Harman acquisition and integration. Board seats at Rainbow Robotics and FläktGroup. Engineering background.

Born 1967

SmartToday; Dealsite; Hankyung, 15 Jul 2026

Choi Yun-seok

CFO (전무)

CFO since about 2022; CEO Dec 2025–Jul 2026; returned to CFO Jul 2026

Former CFO of Gong Cha Korea and ESG Co.; management planning, M&A and accounting

—

Kukinews, Nov 2022; Newsis, Jul 2026

Kim Taek-soo

CTO and Head of R&D

Since 4 Aug 2026

Samsung Advanced Institute of Technology; Vuno (Korean medical AI); Stanford PhD. Experience from technology development through clinical, regulatory approval and commercialisation.

—

Dealsite, 4 Aug 2026; Asia Economy, Oct 2026

Bae Jeong-hee

EVP, Chief Commercial Officer, Head of GTM Center

Since Oct 2026

Korea University; LG CNS systems engineer; Harvard MBA; Monitor Group; Deloitte Consulting; partner at Bain & Company, latterly leading AI and digital strategy. Brand launches and market entry across about 30 countries.

—

Asia Economy, 12 Oct 2026

Andrea Gaeta Lima

CEO, MedSystems (Brazil)

Since about Mar 2026

Former head of Allergan Aesthetics Brazil (AbbVie)

—

Techleap/Edaily, Mar 2026; Times Brasil, Jul 2026

Tadashi Yoshikawa

President, Classys Japan

Since Feb–Mar 2025

Former CEO of HydraFacial Japan and Cynosure Japan; 30+ years at global companies

—

Venture Square, Mar 2025

Baek Seung-han

Former CEO

Nov 2022–Dec 2025

Led the Ilooda merger, US, Europe and Japan entry, and the MedSystems deal

—

Kukinews; Beauty Matter

Jung Sung-jae

Founder; former CEO and controlling shareholder

2007–2022

Dermatologist (Hanyang University BSc/MSc); co-creator of Dr. Jart+. Forbes estimated net worth US$760 m (2025).

Born Oct 1967

Wikipedia

“—” = not publicly disclosed.

Major Shareholders

HolderStake (%)Date / basisSource

BCPE Centur Investments, LP (Bain Capital) and affiliate

49.1

Jul 2026, "BCPE and 1 other"

Kiwoom Securities, 16 Jul 2026

BCPE (alternative calculation)

about 45.9

54.16% (Feb 2026) less the 8.24% block sale

IB Tomato, Feb 2026; Money Today, Jun 2026

Capital Research and Management Company

6.16

27 Jul 2026, 4,020,083 shares, passive investment

Kormedi, citing the large-holding report

Treasury shares

0.022026

Butler.works

Foreign ownership, all holders

67.97

8 Oct 2026

JoongAng Economy News

Competitive Landscape

Key Competitors

CompetitorListing / ownerOverlapping productsRelative positioning vs CLASSYS

Merz Aesthetics

Private (Merz Group)

Ultherapy (HIFU), the FDA-cleared US reference device

Premium global HIFU incumbent. CLASSYS's US HIFU trial uses Ulthera as comparator. Revenue not disclosed.

Solta Medical

Bausch Health subsidiary

Thermage FLX/CPT (monopolar RF)

Premium monopolar RF incumbent. Volnewmer is positioned as an alternative and tested against Thermage CPT.

InMode

Nasdaq: INMD

Morpheus8 (MNRF), RF platforms

FY2025 revenue US$370.5 m (−6%), GAAP operating margin 23% (InMode FY2025 release). Strong US MNRF presence; competes with Quadessy.

Sisram Medical (Alma Lasers)

HKEX: 1696 (Fosun)

Lasers, RF, HIFU-adjacent, injectables

FY2025 revenue US$365.3 m (+4.7%); operating income US$27.0 m (Sisram 2025 Annual Report; StockAnalysis). Broad portfolio with lower margins.

Wontech

KOSDAQ: 336570

Oligio (monopolar RF), Picocare (laser)

FY2025 revenue KRW 156.8 bn (+36.1%), OP KRW 51.7 bn (Medifo News, 2026). Closest Korean monopolar-RF rival to Volnewmer. Expanding direct sales in Thailand, US, Japan and China.

Jeisys Medical

—

Potenza (MNRF), Density (RF), Linear Z (HIFU)

Korean multi-modality rival.

Hironic

—

Doublo (HIFU)

Korean HIFU competitor.

Cynosure Lutronic

Private (merged entity)

Lasers, RF (e.g. Lutronic devices)

Laser and RF overlap.

BTL Aesthetics

Private

RF and body/face energy devices

Global device marketer. Financials not publicly disclosed.

Sofwave Medical

TASE

SUPERB ultrasound lifting

US ultrasound tightening competitor.

Cutera

—

Lasers and RF

US laser and RF overlap.

Peer Comparison FY2025

CompanyFY2025 revenue (USD Mn)Revenue growth (%)Operating margin (%)R&D (% of revenue)

CLASSYS

23638.650.75.2

InMode

370.5-6.023.0—

Sisram Medical

365.34.77.44.6

Wontech

11036.133.0—

Company Snapshot

$237M

Revenue

537

Employees

2007

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Best-in-class profitability: FY2025 operating margin of 50.7% and EBITDA margin of 55.0% (IR Book 4Q25), against 23% at InMode and 7.4% at Sisram.
  • Recurring revenue base: consumables of KRW 154.6 bn were 45.9% of FY2025 revenue, and overseas consumables grew more than 30% YoY in 2Q26 (IR Book 2Q26).
  • Large installed base: more than 48,000 cumulative installations (IR Book 2Q26); Ultraformer ex-Korea 14,000+; Volnewmer 3,200+ across Korea and ex-Korea (IR Book 4Q25).
  • Long record of high growth: revenue CAGR of 35% over FY2021–25 and 21 consecutive quarters of YoY revenue growth through 2Q26 (Eugene, Aug 2026).
  • Diversified geography: more than two-thirds of revenue comes from overseas (66.7% in FY2025), spread across APAC, EMEA and the Americas.
  • Low leverage: equity is about 72% of assets (Jun 2026); the only named borrowing is a KRW 61 bn HQ loan; no bonds.
  • Clinical evidence programme: a head-to-head study against Thermage CPT completed, and an FDA IDE pivotal study against Ulthera recruiting (ClinicalTrials.gov).

Weaknesses

  • Margin dilution from vertical integration: consolidated operating margin fell from 51.6% (2Q25) to 41.6% (2Q26); the standalone margin is still 50.8% (IR Book 2Q26).
  • Korean business contracting: Korea revenue was −25.3% YoY in 2Q26 and Korean devices −39.4% (IR Book 2Q26).
  • Guidance credibility: FY2025 landed just below the raised guidance range (KRW 336.8 bn against KRW 340–360 bn), and FY2026 guidance was cut 9% at the midpoint (KRW 490 bn to 445 bn).
  • Leadership instability: three CEOs between Dec 2025 and Jul 2026 (Newsis, Jul 2026).
  • Working-capital intensity rising: receivables up from KRW 48.4 bn to KRW 98.4 bn and inventories from KRW 30.1 bn to KRW 64.9 bn in six months (IR Book 2Q26).
  • New-product execution: Quadessy was relaunched in an improved version after customer feedback (Kiwoom, Jul 2026; IR Book 2Q26).

Opportunities

  • US HIFU approval: a successful Ultraformer MPT PLUS IDE study could open the US HIFU market, where Ulthera is the main FDA-cleared incumbent (NCT07229430; company target 2027).
  • China entry: Volnewmer NMPA approval is expected around Dec 2026, with a distributor already signed (Samsung Securities, Jul 2026; IR Book 4Q25).
  • Capturing Brazilian distribution margin: MedSystems had about KRW 135 bn sales, with more than 60% from Classys products (Techleap; BizWatch).
  • Japan direct sales: the target is about KRW 50 bn of Japanese revenue within three years (Medifo News, Mar 2025), against KRW 14.2 bn in FY2024.
  • Volnewmer as the next flagship: management targets more than 2,000 units a year.
  • Strategic sale or change of control: Bain's exit could attract a strategic buyer. IB Tomato reported a seller valuation of about KRW 4 tn sought in Feb 2026, against a current market cap of about KRW 1.85 tn.

Threats

  • Overhang from Bain's remaining stake: about 46–49% still held after two block sales at discounts (May 2025, H1 2026).
  • Holdco leverage: the KRW 930 bn refinancing is secured on Classys shares (Dealsite, Dec 2025). A falling share price tightens loan-to-value covenants (terms not disclosed).
  • Korean and Asian price competition: Wontech grew revenue 36.1% in FY2025 with Oligio monopolar RF, directly against Volnewmer.
  • Brazilian credit and macro risk: bad-debt provisions on MedSystems receivables in 2025 before the acquisition (Kiwoom, Oct 2025 and Jan 2026).
  • US demand softness: InMode revenue fell 6% in FY2025, citing US weakness.
  • Regulatory delays: the timing of US HIFU approval differs between the company (2027) and Daishin (2028).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 20251Q25 results: revenue KRW 77.1 bn (+53.1%), OP KRW 38.8 bn; FY2025 guidance raised to KRW 340–360 bn IR Book 1Q25Peak of growth momentum
May 2025Volnewmer receives CE MDR SmartToday, Aug 2025Opens the EU market
16 May 2025Bain sells 6% in a block at a 10.9% discount; stock −6.9% SmartTodayShows overhang risk
Jul 2025Quadessy MNRF launched Eugene, May 2026First new platform after the merger
11 Aug 20252Q25 results: revenue KRW 83.3 bn (+41.8%), OP KRW 43.0 bn (+37.9%); device sales +47% SmartToday, Aug 2025Sixth consecutive record quarter
Aug 2025Ultraformer MPT receives CE certification Yuanta, Aug 2025Full HIFU and RF line-up in the EU
24 Oct 2025Agreement to acquire 77.5% of JL Health (MedSystems) MedSystems IR BookStrategic shift to direct distribution
10 Nov 20253Q25 results: revenue KRW 83.0 bn (+39.7%), OP KRW 37.6 bn; YTD revenue exceeds FY2024 IR Book 3Q25Margin dips on mix, marketing and acquisition fees
15–16 Nov 2025Classys Global Customer Summit Japan (Tokyo), about 150 Asian physicians Venture Square, Nov 2025First large event since Classys Japan opened
28 Nov 2025Shrink Home Lift-to-Glow launched IR Book 4Q25B2C expansion
Dec 2025CEO change: Baek Seung-han replaced by Choi Yun-seok Newsis, Jul 2026First of two CEO changes
Dec 2025Bain completes KRW 930 bn holdco refinancing with about KRW 300 bn recap Dealsite, 3 Dec 2025Raises PE leverage
13 Feb 2026FY2025 results: revenue KRW 336.8 bn, OP KRW 170.6 bn (50.7%); 2026 guidance KRW 470–510 bn IR Book 4Q25Record year
Feb 2026Brokers raise targets: Daishin KRW 88,000; Hyundai Motor Securities KRW 89,000; Hana KRW 92,000 IB Tomato, Feb 2026; Hana, Feb 2026Sentiment peak; 52-week high KRW 77,600
Mar 2026DPS KRW 1,000 (payout 49.4%) approved. Treasury shares cancelled (270,000 shares, derived from share count). Samsung Securities, Apr 2026Shareholder returns
Mar 2026MedSystems acquisition completed; Andrea Gaeta Lima named CEO Techleap/EdailyBrazil direct operations begin
H1 2026Bain sells 8.24% (about KRW 324 bn) Money Today, Jun 2026Second block exit
13 May 20261Q26 results: revenue KRW 87.2 bn (+13.1%), OP KRW 37.2 bn (−4.1%), about 15–17% below consensus IR Book 1Q26; KyoboFirst YoY OP decline in years
19 May 2026Attends Citi Pan-Asia Conference IRGOInvestor outreach
Jun 2026Presents at Jefferies Global Healthcare Conference; reiterates US$1 bn by 2030 QuartrInvestor outreach
15 Jul 2026Yoon Jun-oh (ex-Samsung EVP) appointed CEO; Choi returns to CFO Dealsite; NewsisStrategy and M&A-oriented leadership
Jul 2026GTM Center created to unify marketing and sales Asia Economy, Oct 2026Commercial reorganisation
14–27 Jul 2026Capital Research raises its stake to 6.16% KormediLong-only buying near lows
22–23 Jul 2026Samsung cuts target to KRW 70,000; IBK initiates at KRW 62,000; Kyobo keeps KRW 70,000 but warns on Brazil and Quadessy Asia Economy; Nate/NewspimDowngrade cycle begins
4 Aug 2026CTO Kim Taek-soo appointed DealsiteR&D and AI agenda
12 Aug 20262Q26: revenue KRW 105.5 bn (+26.7%), OP KRW 43.9 bn (+2.2%, 8–13% below consensus); Korea −25.3%; FY2026 guidance cut to KRW 445 bn IR Book 2Q26; EdailyMajor negative catalyst
13 Aug 2026Targets cut: Kiwoom KRW 54,000; Daishin KRW 60,000 (−26%); Mirae KRW 64,000; Eugene KRW 67,000 StockHub (broker summaries)Consensus reset
20 Aug 202652-week low of KRW 33,350 on a day KOSDAQ rose 2% StockHub market noteStock-specific de-rating
Aug–Sep 2026IR events (19 Aug, 26 Aug, 1 Sep); large-holding report (3 Sep) Butler.works (DART list)Investor engagement
12 Oct 2026Bae Jeong-hee (ex-Bain & Co partner) appointed CCO and GTM Center head Asia Economy; EdailyCompletes new top team
Oct 2026Stock hits a new 52-week low of KRW 26,550; closes KRW 28,350 on 19 Oct AlphaSquare; JoongAng Economy NewsAbout 64% below the 52-week high

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Revenue by Segment: Totals: Total revenue rose from KRW 242.9 Bn in FY2024 to KRW 336.8 Bn in FY2025.
CLASSYS Inc. — Revenue by Segment: Totals
Series (KRW Bn)FY2024FY2025
Total revenue242.9336.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Classys IR Book (Finance) 4Q25, 13 Feb 2026 (classys.com)
  2. Classys IR Book (Finance) 2Q26, 12 Aug 2026 (classys.com)
  3. Classys IR Book (Finance) 3Q25, 10 Nov 2025 (classys.com)
  4. Classys IR Book (Finance) 1Q25, 12 May 2025 (classys.com)
  5. Classys IR Book, MedSystems acquisition, 24 Oct 2025 (classys.com)
  6. Classys IR Book 2023 (Korean): IR.pdf (files-scs.pstatic.net)
  7. Quartr event summaries (Q1–Q4 2025, Q1–Q2 2026) (quartr.com)
  8. Butler.works company page (DART-derived annual figures) (butler.works)
  9. Edaily on the guidance cut, Aug 2026 (edaily.co.kr)
  10. Asia Economy, 2Q26 results (view.asiae.co.kr)
  11. Asia Economy, CCO appointment, 12 Oct 2026 (core.asiae.co.kr)
  12. Dealsite, CEO appointment, 15 Jul 2026 (dealsite.co.kr)
  13. Dealsite, governance and exit analysis, 21 Jul 2026 (dealsite.co.kr)
  14. Dealsite, CTO appointment, 4 Aug 2026 (dealsite.co.kr)
  15. Dealsite, Bain holdco refinancing, Dec 2025 (dealsite.co.kr)
  16. Newsis, CEO turnover, 16 Jul 2026 (newsis.com)
  17. Hankyung, CEO appointment (hankyung.com)
  18. SmartToday, Bain 6% block sale, May 2025 (smarttoday.co.kr)
  19. IB Tomato, Bain exit valuation, Feb 2026 (newstomato.com)
  20. StockHub / Money Today, Bain 8.24% sale (stockhub.kr)
  21. Kiwoom Securities, Jul 2026 preview (bbn.kiwoom.com)
  22. Kiwoom 2Q26 review summary (stockhub.kr)
  23. Daishin target cut summary (stockhub.kr)
  24. Kyobo Securities, May 2026 (stock.pstatic.net)
  25. Yuanta Securities, Apr 2026 (stock.pstatic.net)
  26. Samsung Securities, Apr 2026 (samsungpop.com)
  27. Kormedi, Capital Research stake (kormedi.com)
  28. AlphaSquare quote, 19 Oct 2026 (alphasquare.co.kr)
  29. JoongAng Economy News, 8 Oct 2026 quote (joongangenews.com)
  30. Medigate News, Ilooda merger completion and 2030 targets (medigatenews.com)
  31. SmartToday, Ilooda merger terms (smarttoday.co.kr)
  32. LexLatin, JL Health transaction (lexlatin.com)
  33. Techleap / Edaily, MedSystems completion (finder.techleap.nl)
  34. Beauty Matter, JL Health deal (beautymatter.com)
  35. Times Brasil, CEO and 2030 target (timesbrasil.com.br)
  36. BizWatch, MedSystems margin analysis (news.bizwatch.co.kr)
  37. ClinicalTrials.gov NCT07229430 (clinicaltrials.gov)
  38. ClinicalTrials.gov NCT06657365 (clinicaltrials.gov)
  39. Cartessa Aesthetics, JPM 2025 (cartessaaesthetics.com)
  40. InMode FY2025 results (barchart.com)
  41. Sisram Medical FY2025 financials (stockanalysis.com)
  42. Wontech FY2025 results (medifonews.com)
  43. Wikipedia, Classys / Jung Sung-jae (en.wikipedia.org)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.